Jpmorgan Chase & CO Aligos Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.89 - $28.0 $2,781 - $87,500	-3,125 Reduced 82.19%	677 $1,000
Q3 2022 Nov 14, 2022	BUY	$1.06 - $27.5 $2,363 - $61,325	2,230 Added 141.86%	3,802 $5,000
Q2 2022 Aug 11, 2022	SELL	$1.04 - $2.14 $13,626 - $28,038	-13,102 Reduced 89.29%	1,572 $2,000
Q1 2022 May 11, 2022	BUY	$2.08 - $12.2 $605 - $3,550	291 Added 2.02%	14,674 $31,000
Q4 2021 Feb 10, 2022	SELL	$11.48 - $17.69 $14,935 - $23,014	-1,301 Reduced 8.3%	14,383 $170,000
Q3 2021 Nov 12, 2021	BUY	$14.57 - $17.72 $228,515 - $277,920	15,684 New	15,684 $244,000

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.3B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.